Product Images Mvasi

This is a graph showing the proportion surviving over a period of 48 months after a randomized treatment. The graph includes two treatment groups: one with chemotherapy only and the other with chemotherapy plus Bevacizumab. The text also shows the number of participants at risk in each treatment group at different time points.*

This appears to be a chart or graph related to a medical study. It includes categories like "Proportion Surviving," "No. of Patients at Risk," and "Duration of Survival (months)." There are also abbreviations for "PC" and "Bev" and a number of numerical values. However, without more context it is difficult to determine the exact meaning or significance of this data.*

This text is a table showing the number of patients at risk and the progression-free survival in months, with different values for CPP, CPBI5, and CPBI5H. The number of patients for each value is also provided. There is no available information on what this table is representing or what CPP, CPBI5, and CPBI5H stand for.*

This appears to be a chart or graph displaying the "Duration of Progression-free Survival" in months for two different treatments, "CT" (with 182 subjects) and "CT+Bev" (with 179 subjects). The percentages appear to represent the "Proportion Progression-free" at certain time points. Without further context, it is difficult to provide more information or specific insights.*

The text provided seems to be a combination of numerical values and labels without a clear context or objective. With this information only, it is not possible to generate a useful description.*

This is a description of a medication labeled as NDC55513-206-01. It is a sterile solution intended for intravenous infusion after dilution. The concentration is 100 mg/4 mL (25 mg/mL). It is packaged as a single-dose vial and any unused portion should be discarded. The medication must be stored refrigerated at a temperature range of 2°C to 8°C (36°F to 46°F) to protect it from light. The solution must not be frozen or shaken. This medication does not contain any preservatives. The text also indicates that this medication is available by prescription only.*

This is a description of a drug called MVASI, which contains bevacizumab-awnt. It is available in two strengths, 400mg/16 mL and 300mg/16 mL, and is administered through intravenous infusion after dilution. The drug must be stored in a cool, dark place and should not be frozen or shaken. This is a sterile solution that should only be used with a prescription.*